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Zurich, 3rd March, 2011 
 
RE:  JNEN 10-332 
 
Dear Professor Sobel, 
 
Please find attached our revised manuscript entitled:  
„ Impairment of tight junctions and glucose transport in endothelial cells of human 
cerebral cavernous malformation” 
by H. Schneider, N. H. Ulrich, M. Errede, D. Virgintino, K. Frei and H. Bertalanffy. 
 
Due to the reviewers concerns, you considered a revised manuscript if we satisfactorily 
address their queries, criticisms and suggestions. This revised manuscript takes into account 
the reviewers concerns, which we address in a detailed point-by-point reply, which you can 
find below. 
 
Our data revealed that improper tight junction assembly reflects a hallmark in the 
pathogenesis of cerebral cavernous malformations (CCM). There is strong evidence that we 
could identify proteins that are responsible for the resulting vascular matrix instability seen in 
CCM, which might lead to hemorrhage into the surrounding brain tissue. 
 
As already mentioned, we focused our analysis on cell biological differences regulating the 
BBB under physiological conditions compared to the situation in CCM pathology. This is in 
contrast to previous studies in CCM focusing mainly on the genetic mutations of CCM genes 
1, 2 and 3. 
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Our findings are of particular importance for the molecular understanding of CCM 
pathophysiology because obvious alterations in tight junction assembly and metabolic 
processes in endothelial cells in examined lesions may contribute to a new 
pathophysiological process and present a possible therapeutic concept in the future. 
 
We would be grateful if you would consider our reviewed manuscript for publication in your 
journal. 
We assure you that neither the submitted material herein nor portions thereof have been 
published previously or are under consideration for publication elsewhere and hence present 
no conflicts of interest.  
 
 
Sincerely yours, 
 
Hannah Schneider 
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Reply to the Referees’ Comments: 
 
Reviewer #1: 
 
In this revised version the problem with Figures 1-3 persists. The authors included immunostaining 
for CD31 as suggested, however, the high magnification of the images still does not allow the reader 
to identify endothelia of a cavernoma. Fig. 1 A for example shows a small vessel surrounded by many 
cells of unknown identity. This feature is not typical for a cavernoma since the vessel is very small, 
only about four nuclei in diameter. Typical cavernoma vessels are larger and one vessel neighbors 
the next. The same holds true for Figure 5. The vessels in A, B and C seem to be dilated capillaries and 
are not typical for cavernoma vessels. 
Now, we additionally included comparable figures of paraffin sections stained for occludin and 
GLUT-1 on one of the studied cases. These two figures are put within the revised manuscript as 
supplemental figures (Fig. S1 and S2) and are mentioned within the results section. The diameters 
of the vessels shown in the images are bigger compared to some of the vessels shown in figures 1-
6, reflecting more clearly dilated capillaries in CCM tissue. In literature, CCM is defined as a vessel 
malformation where one vessel neighbors the next. We often observed that dilated capillaries are 
surrounded by an extracellular matrix-like material (containing collagens). Those ECM-like layers 
can have a large extend why it is possible to get the impression of “single” vessels although one 
neighbours the next. 
 
2 - In the discussion the authors provide a hypothesis for the discrepancy between the fluorescence 
intensitiy (FI) and the microarray data. Since the samples come from different sets of cavernomas, 
the discrepancy might as well indicate that the results are not representative for cavernomas in 
general. 
We decided to additionally analyze gene expression with quantitative real-time RT-PCR. We 
suggest that different results of protein and RNA expression might came from the fact, that control 
tissues used for the two experiments were different: superficial temporal arteries (STAs) for 
microarrays vesus normal brain tissue (NBT) for immunohistochemistry. mRNA expression was 
analyzed using eight NBTs and eight CCMs (among them tissue of cases studied in IHC). We could 
show that mRNA is downregulated for all proteins we analyzed and herewith strengthens our 
protein data. STA might not be an adequate control tissue, since it doesn’t reflect a microvessel 
phenotype as dilated CCM vessels do. The composition of big arteries is different to the 
composition of microvessels including gene and protein expression patterns. This could explain 
different results for gene expression between microarrays and qRT-PCR experiments. We decided 
to remove the microarray data out of the manuscript and therefore also had to remove the two 
responsible authors. 
 
 
Reviewer #2: 
 
It is credible that the TJ proteins occludin, claudin-5 and ZO-1 become redistributed in CCM. 
Additionally, the expression of adherens junction (AJ) proteins should be shown in particular as 
CCM1/Krit1 interacts with beta-catenin to assemble the junctional complex. In this respect the 
available literature (Serebriiskii et al., 1997; Glading et al., 2007; Voss et al., 2007, etc.) should be 
cited and discussed with regard to the present data. 
We discussed this issue but we did not examine our samples for beta-catenin or further adherens 
junction proteins. This topic is very interesting and since AJ cross-react with TJ, we agree that AJP 
should be also analyzed in CCM tissue. Then, also studies of mRNA expression and interactions 
between would be necessary to find out more about how those structures are impaired in the 
context of CCM pathology. Therefore we decided to put this on the list for future publications. 
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The authors discuss the distributed staining of TJ protein around CCM blood vessels as "surrounding 
parenchymal staining". However, these could well be endothelial cells detached from the vessels. 
PECAM/CD31 might not be the best marker to evaluate co-localization in this case as it is also 
junctional localized and hence redistributed in CCM. vWF could be an alternative. 
We did additional vWF staining as EC-marker together with occludin and GLUT-1, which can be 
found in the supplemental figures (Fig. S1 and S2). 
 
In general it would be advisable to add an inscription at least to figures 1-4, making it much easier to 
understand. Furthermore, the order of the figures named in the text should be consecutive. Most 
prominently, the authors describe the GLUT-1 expression in the second section of the "Results" part, 
referring to Figure 4 although in the first section they end with Figure 6. 
We added inscriptions in Fig. 1-6 to make it easier to understand. And we also changed the order 
of Fig. 4-6, now being in a consecutive order as named in the text. 
 
As the authors make the point that concomitantly with GLUT-1 misexpression the blood-brain barrier 
is hampered, it would be informative to stain the CCM samples for human IgG and/or fibronectin to 
evaluate vessel leakage. 
We co-stained CCM and control tissue for fibronectin and EC-marker coll VI (Fig. 7). In contrast to 
NBT, where fibronectin is located homogenously along vessel walls, the staining pattern is very 
irregular in CCM tissue reflecting vessel leakage. 
 
With regard to the microarray analysis, it would be important to validate the finding by quantitative 
RT-PCR analysis. 
This we did and results are shown in Fig. 9. Above, we already commented on that issue. 
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Abstract 
 
Cerebral cavernous malformations (CCMs) often cause hemorrhages which can result in severe 
symptoms like hemiparesis or seizures. The underlying mechanism behind the aggressive behavior of 
a CCM lesion is undetermined to date, but alterations of vascular matrix components may be 
responsible. Hence, we investigated the localization of the tight junction proteins (TJPs) occludin, 
claudin-5 and ZO-1 within endothelial cells. Additionally, we examined the expression of glucose 
transporter 1 (GLUT-1) which is sensitive to alterations in TJP levels. Seven CCM and five control 
(normal brain tissue) specimens were examined by fluorescent immunohistochemistry for occludin, 
claudin-5, ZO-1 and GLUT-1. Our protein expression analysis showed that occludin, claudin-5 and 
ZO-1 were downregulated at intercellular contact sites and partly redistributed within the surrounding 
tissue in all patients examined. We also observed a massive reduction of GLUT-1 that was not 
observed in any of the control specimens. Corresponding analysis using quantitative real-time RT-
PCR (qRT-PCR), revealed a significant downregulation in mRNA-expression of occludin, claudin-5, 
ZO-1 and GLUT-1.  
 
Keywords: cerebral cavernous malformation, tight junctions, occludin, claudin-5, ZO-1, GLUT-
1 
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Introduction 
 
Cerebral cavernous malformations and arteriovenous malformations (AVMs) present the most 
common lesion subtypes of vascular malformations of the brain (VMBs), affecting more than 0.5% of 
the population (1-4). CCMs are composed of dilated, blood filled capillary clusters lined by 
endothelium, lacking intervening brain parenchyma. Due to the expression of angiogenic factors, they 
reflect more a developing rather than a mature vessel phenotype (1, 3, 5-7). Cavernous malformations 
occur sporadically, as a single lesion, or as an inherited, autosomal dominant form with multiple 
lesions (8). To date, mutations in three genes have been identified to cause the familial form of the 
disease: CCM1/KRIT1, CCM2/MGC4607 and CCM3/PDCD10 (9). It has been hypothesized that a 
second hit in the somatic allele is necessary to cause CCM formation. Indeed, in 2005, a biallelic 
CCM1 somatic and germ line mutation has been shown in a surgically excised human lesion for the 
first time (10). In the meantime, biallelic mutations were also reported for CCM2 and CCM3 (11). 
Furthermore, transgenic mice heterozygous for Ccm1, only develop CCM lesions when they exhibit an 
additional homozygous knockout of the tumor suppressor gene Trp53 (ccm1
+/-
 Trp53
-/-
). Similarly, 
heterozygous mice with Ccm2
±
 only form CCM lesions when sensitized by a second hit (12, 13). This 
further supports the hypothesis of a second genetic somatic mutation in CCMs.  
Recently, it was shown that CCM1 represents an antiangiogenic protein and that gene mutations in  
KRIT1 correlate with excessive capillary sprouting, which is characteristic for human CCM pathology 
(7). PTEN promoter methylation, HEG transmembrane receptor expression, RhoA GTPase and ROCK 
activation are involved in the pathogenesis (14-17) and therefore have also been suggested to 
contribute to the mechanism of lesion formation.  
Endothelial cells (ECs) are the major component of vessel walls. It is thought that they play a central 
role in the clinical behavior of a cerebral vascular malformation showing abnormal ultrastructural 
pathological features (18). The thin walls of CCM vessels possess limited number of intact 
interendothelial tight junctions, which may contribute to the propensity of recurrent microhemorrhage 
seen in CCMs (19). There is growing evidence that an impairment of the blood-brain barrier (BBB) 
correlates with a decrease of tight junctions in the endothelial layer and furthermore that CCM1 as 
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well as CCM2 could play a junction stabilizing role (15, 17, 20, 21). Recently, it was shown TJP 
occludin to be involved in intercellular gap formation reflecting BBB breakdown in porcine brain 
capillary endothelial cells (22).  
Tight junctions are located at the lateral apical side of the cell membrane in regions of close cell–cell 
contacts, e.g. in the cerebral microcapillary endothelium. They turn cell-to-cell contacts into zones of 
tight adherence thereby inhibiting the paracellular pathway for drugs or solutes from plasma into the 
central nervous system (CNS) (23). Different integral membrane proteins, associated cytoplasmatic 
proteins and extracellular matrix components are involved in the proper assembly of tight junction 
complexes (24). Two junctional core proteins, occludin and claudin-5 play a key role in BBB integrity 
in the microvascular endothelium. Both consist of four transmembrane domains, intracellular N- and 
C-termini, and two extracellular domains that might interact with cell membranes of vicinal cells thus 
sealing the intercellular clefts (22, 25, 26). Different gain-of-function and loss-of-function experiments 
reveal that claudin-5 is involved in the structure of TJ strands and cell adhesion, whereas occludin 
probably has some accessory functions (27). Furthermore, adaptor/scaffold proteins such as zonula 
occludens (ZO-1, ZO-2 and ZO-3) connect TJ-associated integral membrane proteins to the actin 
cytoskeleton and other structural proteins. The first reported linker protein, ZO-1 directly interacts 
with occludin and claudins and is essential for TJ formation (27, 28). It was hypothesized that the 
interaction of occludin with ZO-1 modulates its function in sealing the junction, since paracellular 
permeability increases when an imbalance occurs between occludin and ZO-1 molecules (29, 30). 
The localization of glucose transporter 1 (GLUT-l) in ECs of microvessels is considered as an 
indicator of a functioning BBB (31-33). The protein is widely expressed in adult tissues, but it is most 
abundant in fibroblasts, erythrocytes and endothelial cells with low levels of expression in muscle, 
liver and adipose tissue (34-36). In healthy brain endothelium, TJ sealing of the interendothelial clefts 
is linked to the expression of GLUT-1. Alterations in transporter protein expression are directly related 
to an increased permeability of endothelial layers in the brain and also linked to alterations in TJ 
properties  (31-33). 
To date, the role of TJs and their core proteins occludin and claudin-5 are not fully understood in the 
context of CCM lesions. But there is growing evidence that vascular development and endothelial 
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permeability are dysregulated (37). In brain tumor pathology it was shown, that decreased expression 
of GLUT-1 is coupled to alterations in TJP expression levels and consequently BBB opening (38). 
Therefore, we analyzed the expression of TJPs (occludin, claudin-5 and ZO-1) and the transporter 
protein GLUT-1 by classic immunohistochemistry and confocal fluorescent microscopy on cryo- and 
paraffin-sections of seven CCM specimens and five control samples (normal brain tissue; NBT). NBT 
specimens were received from temporal lobe biopsy during selective amygdalohippocampectomy 
from patients with temporal lobe epilepsy (TLE). Mean fluorescence intensity was further quantified. 
Furthermore, qRT-PCR was also performed to compare mRNA expression levels of TJPs and GLUT-
1 in eight CCM versus eight control samples.  
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Materials and Methods 
 
Patients and tissue specimens 
Twelve CCM specimens were obtained from patients undergoing neurosurgical resection. Thirteen 
human control tissue specimens (NBT) were received from temporal lobe biopsy during selective 
amygdalohippocampectomy from patients with TLE. The median age of the seven female and five 
male patients was 38 (range 23 to 52 years). The clinical data of the twelve CCM patients is 
summarized in Table 2. List of patients included in this study is based on the consensus 
recommendations for minimal reporting variables in CCM clinical research (39-41). The decision for 
surgical resection was made based on computed tomography scan and magnetic resonance imaging. 
Tissue specimens were immediately transferred to the laboratory on ice and divided for snap-frozen 
preparation and in vitro experiments. Samples were snap-frozen in liquid nitrogen (NO2) and 
embedded in TissueTek O.C.T (Satura Finetek Europe, Zoeterwoude, Netherlands) before analysis. 
Additionally, histological diagnosis was obtained by routine clinical neuropathological examination 
and classified according to the World Health Organization standards (Institute of Neuropathology, 
University Hospital Zurich, Switzerland).  
 
Immunofluorescence, laser scanning confocal microscopy and fluorescence microscopy analysis  
Immunofluorescence analysis was done by three different protocols. First, 6 μm cryosections were cut 
with a Leica cryostat, mounted on Superfrost
®
Plus slides (Menzel-Glaser, Braunschweig, Germany), 
fixed with acetone p.a. for 10 min at room temperature (RT) and stored at -80°C till further use. For 
analysis, slides were acetone-fixed for 5 min at RT and air-dried. Sections were incubated with 3% 
peroxide to quench endogenous peroxidase activity and washed with PBS (pH 7.4). Unspecific 
binding sites were blocked with blocking solution (Candor, Weiβensberg, Germany) for 25 min at RT. 
For indirect immunofluorescence, polyclonal rabbit anti-human claudin-5-antibody (5 μg/ml; Abcam, 
Cambridge, UK), monoclonal mouse anti-human occludin-antibody (4 μg/ml; Invitrogen, Carlsbad, 
CA USA), monoclonal mouse anti-human GLUT-1-antibody (1 μg/ml; Abcam, Cambridge, UK), 
monoclonal mouse anti-human fibronectin (2 µg/ml; Abcam, Cambridge, UK), mouse monoclonal 
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anti-human CD31 (10μg/ml; DAKO, Glostrup, DK), monoclonal rabbit anti-human CD31 (1:40; 
epitomics, Burlingame, CA, USA),  monoclonal mouse anti-human collagen-IV-antibody (2 μg/ml; 
DAKO, Glostrup, DK) and polyclonal rabbit anti-human collagen-VI-antibody (2 µg/ml; Abcam, 
Cambridge, UK) were incubated at 37°C for 1h. Appropriate secondary antibodies, ALEXA 488-
conjugated (goat anti-rabbit and goat anti-mouse 1:100, Invitrogen, Carlsbad, CA, USA) or ALEXA 
594-conjugated secondary antibody antibody (goat anti-rabbit and goat anti-mouse, 1:100, Invitrogen 
Carlsbad, CA, USA) were incubated for 25 min at RT. All antibodies were diluted in “Antibody 
Dilution Buffer” (DCS, Hamburg, Germany). Between each step, the sections were washed in PBS 
three times 5 min each. Control stainings included the isotype matched primary monoclonal 
antibodies. In all cases, the result of each negative control confirmed the specificity of the 
corresponding antibody staining. Specimens were mounted in fluorescent mounting medium (DAKO, 
Glostrup, DK) and sections were viewed on a Leica TCS SP5 (Leica, Wetzlar, Germany) confocal 
laser scanning microscope (CLSM) using 63x and 100x objectives. Confocal images were taken at 1-2 
μm intervals through the z-axis of the section. Projection images formed by serial optical planes were 
analyzed, digitally recorded, and stored as tagged image file format files using Adobe Photoshop CS3 
software (Adobe Systems, San Jose, CA, USA). Second, tissue samples were placed into 4% neutral 
buffered formalin for twelve hours, and then were processed routinely for paraffin inclusion. Sections 
were obtained at 4 µm intervals using a Microm rotary microtome (Leica, Wetzlar, Germany), put in 
water and mounted to Superfrost
®
Plus slides (Menzel-Glaser, Braunschweig, Germany). After 
rehydration, for antigen retrieval, sections were boiled in a microwave oven in 0.01M citrate buffer 
solution (pH 6) for 20 minutes. Endogenous peroxidase was inactivated with 3% hydrogen peroxide 
and nonspecific antigenic sites were blocked with blocking solution (Candor, Weißensberg, Germany) 
for 25 minutes at RT. As already described above, sections were incubated with primary occludin- (4 
µg/ml, Invitrogen, Carlsbad, CA, USA), GLUT-1- (1 μg/ml; Abcam, Cambridge, UK) and polyclonal 
rabbit anti-human vWF-antibodies (28.5 µg/ml; DAKO, Glostrup, DK) followed by incubation with 
appropriate secondary antibodies, ALEXA 488-conjugated (goat anti-mouse 1:100, Invitrogen, 
Carlsbad, CA, USA) or ALEXA 594-conjugated secondary antibody antibody (goat anti-rabbit, 1:100, 
Invitrogen, Carlsbad, CA, USA). Third, tissue specimens were fixed for 3 h at 4°C by immersion in 
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2% paraformaldehyde plus 0.2% glutaraldehyde solution and washed in PBS (pH 7.6). The blocks of 
tissue were sectioned at 20 μm thickness using a vibrating microtome (Leica, Wetzlar, Germany) and 
sections were collected on polylysine slides (Menzel-Glaser, Braunschweig, Germnay). Heat-mediated 
antigen retrieval was achieved by microwave pre-treatment in 0.01 M citrate buffer (pH 6.0) for 15 
min at 750W. Sections were incubated with PBS/0.5% Triton X-100 for 30 min, blocked with protein 
block serum free (DAKO, Glostrup, DK) for 15 min at RT and incubated overnight at 4 °C with 
primary antibodies at various dilutions: mouse monoclonal anti-human claudin-5 (1:20; Zymed 
Laboratories, Invitrogen, Carlsbad, CA, USA), rabbit polyclonal anti-human occludin (1:50; Zymed 
Laboratories, Invitrogen, Carlsbad, CA, USA), rabbit polyclonal anti-human collagen IV (1:200; Acris 
Antibodies GmbH, Hiddenhausen, Germany), mouse monoclonal anti-human collagen IV (1:50; 
DAKO, Glostrup, DK) and mouse monoclonal anti-human CD31 (1:50; DAKO, Glostrup, DK). A 
mixture of biotinylated horse anti-mouse (1:400; Vector, Vector Laboratories, Inc.; Burlingame, CA, 
USA) or biotinylated goat anti-rabbit IgG (1:400; Vector, Vector Laboratories, Inc.; Burlingame, CA, 
USA) and Alexa568-conjugated goat anti-rabbit (1:400, Invitrogen, Carlsbad, CA, USA) or Alexa555-
conjugated goat anti-mouse IgG (1:400, Invitrogen, Carlsbad, CA, USA) were incubated as secondary 
antibodies for 40 min at RT. Streptavidin Alexa Fuor 488-conjugated (1:400; Invitrogen, Carlsbad, 
CA, USA) was used for staining of claudin-5 and occludin. The slices were counterstained with TO-
PRO-3 (1:10.000 in PBS; Invitrogen, Carlsbad, CA, USA) and finally mounted with Vectashield 
(Vector Vector Laboratories, Inc.; Burlingame, CA, USA) and sealed with nail varnish. The stainings 
were examined under the Leica TCS SP5 confocal laser scanning microscope (Leica, Wetzlar, 
Germany) using a sequential scan procedure during image acquisition of double-labeled sections. 
Confocal images were taken at 250-500 nm intervals through the z-axis of the sections. Images from 
individual optical planes and image projections of stacks of serial optical planes were analyzed by 
Leica confocal software (Multicolor Package; Leica, Wetzlar, Germany). 
 
Image Acquisition, image processing and data analysis  
Digital image processing for the detection and quantification of fluorescent intensitiy (QFI) in human 
CCM and control samples was performed with a conventional light microscope (Axiovert 100, Zeiss, 
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Jena, Germany), a digital microscope camera (AxioCam ICm, Zeiss, Jena, Germany) and the 
AxioVision 4.8 software (Zeiss, Jena, Germany). Fluorescence quantification was sub-divided into 
image acquisition, image preprocessing, and data processing steps (42). All parameters used in the 
acquisition were standardized (detector gain, exposure time) to maintain high reproducibility. Image 
processing of each specimen was provided through region of interest (ROI) analysis. The software 
allows the interactive definition of areas for size and intensity measurements. For data analysis, 
fluorescence intensity/ROI values were obtained for five ROIs/specimen (10 μm2 each). Statistical 
analysis describing the distribution of the intensity of the fluorescence signals was performed to obtain 
graphical representations. 
 
Quantitative RT-PCR analysis 
Differential gene expression levels of claudin-5, occludin, ZO-1 and GLUT-1 were determined by q 
RT-PCR. Therefore, total RNA was isolated from each cavernoma and control tissue sample using the 
RNeasy Mini Kit Isolation System according to the manufactor’s protocol for RNA extraction (Qiagen 
Ltd., Hombrechtikon, Schweiz). 0.5 µg total mRNA of each sample was reverse transcribed to cDNA 
using the High Capacity cDNA Reverse Transcription Kit (ABI, Carlsbad, CA, USA). cDNA was 
used for qRT-PCR with SYBR
®
 Green PCR Master Mix (ABI, Carlsbad, CA, USA) and specific 
primer pairs on a 7900HT Fast Real-Time PCR System with SDS Software v2.4 (ABI, Carlsbad, CA, 
USA). Expression was normalized against the endothelial marker CD31 or vWF. Specific primers 
were designed with the Primer Express 3.0 software (ABI, Carlsbad, CA, USA) and are listed in Table 
1.   
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Statistical analysis 
For quantification and statistical analysis of protein expression levels, experiments were done in 
triplicates analyzing five ROIs/specimen (10μm2) for each patient. Mean fluorescence intensity (MFI) 
values were calculated and averaged. ROIs were selected randomly by criteria that only fluorescent 
signals of vessel wall structures were measured for their intensity. The statistical analysis, using the 
mean fluorescence intensity values of each patient, was performed with Microsoft Excel and 
GraphPad Prism software (version 5 for Windows). To assess whether two independent samples of 
observations come from the same distribution, an unpaired students t-test was used. P-values < 0.01 
were considered as statistically significant. 
mRNA expression levels of each gene were obtained via correction for endothelial density. The results 
are expressed as means ± standard error (SEM). Statistical evaluation was performed with GraphPad 
Prism software (version 5 for Windows). Statistical significance was determined by Mann-Whitney-
Wilcoxon Test . P-values < 0.05 were considered as statistically significant. 
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Results 
 
Comparison of TJPs between CCM and NBT microvessels 
Initially, protein expression patterns of TJPs occludin, claudin-5 and ZO-1 from seven CCM and five 
control specimens were examined on intact vascular structures by fluorescent immunohistochemistry 
and analyzed via laser scanning confocal microscopy (representative images of following samples are 
shown: Fig. 1: CCM#1, CCM#2, c#2 and c#4; Fig. 2: CCM#2,CCM#3, c#2 and c#4; Fig. 3: CCM#2, 
CCM#3, c#1 and c#4 and Fig. S1: CCM#1, c#1). The levels of TJP expression were compared to 
control tissues obtained from patients with temporal lobe epilepsy who had undergone surgery. 
Representative results for two CCM and control specimens, respectively, are shown in Figs. 1-3 and 
S1. To identify endothelial cells (ECs), sections were co-stained for the EC marker protein PECAM-
1/CD31 on cryosections (Fig.1-3: A’’-D’’) and von Willebrand factor (vWF) on paraffin sections (Fig. 
S1: A’’-D’’). Protein expression of occludin, claudin-5 and ZO-1 was clearly decreased in endothelial 
layers of CCM tissue compared to control brain microvessels, which showed a typical linear staining 
pattern at distinct endothelial cell borders. The linear junctional labeling was either discontinuous or 
amorphous and many vessels even appeared negative for TJPs. In several cases, redistribution of 
proteins was observed in the endothelial layer as well as the surrounding tissue (Fig. 1-3: A’-C’). Co-
staining for CD31 and vWF additionally revealed that only microvessels were analyzed for 
impairment in TJP localization.   
We then proceeded to build three dimensional reconstructions of vascular structures to validate the 
immunofluorescence experiments which showed different localization patterns for TJPs along the 
margin of cell–cell contacts and in the surrounding tissue of CCMs when compared to controls (Fig. 4 
and 5). In CCM tissue, in regions where a protein signal could be determined, few vessels showed a 
punctuate labelling for claudin-5 (Fig. 4B/C and 5A/B), in others occludin and claudin-5 were linearly 
arranged along the endothelial cell-cell contacts as it was observed in the vessels of control tissues 
(Fig. 4A; Fig. 5C). In those cases, the fluorescence signal of both proteins was clearly weakened 
compared to the signal intensity in healthy tissue. Furthermore, in vessels of control tissues, occludin 
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and claudin-5 staining was limited to the vascular intima (Fig. 4D/E and 5D), whereas it could also be 
detected in the surrounding tissue in some regions of the CCM sections (Fig. 5A). 
 
GLUT-1 expression in CCM vessels 
Alterations in transporter protein expression are directly related to an increased permeability of 
endothelial layers in the brain and also linked to alterations in TJ properties (31-33).  
To investigate BBB permeability, which not only corresponds to alterations in TJPs but to an 
impairment of GLUT-1 expression, we also stained CCM and control tissue cryosections for this 
transmembrane transporter protein (shown in Fig. 6 for samples: CCM#1, CCM#6, c#1 and c#5 on 
cryosections and Fig. S2: CCM#3, c#1 on paraffin embedded sections). We could observe that 
microvessels of control brain tissues were stained uniformly and showed a high level of GLUT-1 
expression (Fig. 6 and S2: C’-D’). Unlike in controls, GLUT-1 expression was reduced or absent in 
CCM specimens (Fig. 6 and S2: A’-B’).  As an internal positive control, erythrocytes were stained in 
every sample, to reflect membranous GLUT-1 activity (Fig. 6 and S2: B’). To conclude, linear TJP 
localization at EC boarders was clearly disrupted and accompanied by a massive reduction of GLUT-1 
staining. This reflects an impairment of the BBB, which is supported by vessel leakage illustrated in 
Fig. 7 by an irregular fibronectin staining around CCM microvessels.  
 
Alterations in TJP and GLUT-1 expression in CCMs 
For further analysis, alterations in protein expression levels were quantified by determining signal 
intensities of immunofluorescent labeled cryosections of CCM against the intensities in control 
specimens. As described above, a strong reduction of TJP and GLUT-1 levels were observed along EC 
cell borders, corresponding to decreased FI per ROI (Fig. 8). A drop of occludin-, claudin-5-, ZO-1- 
and GLUT-1-fluorescence signal was determined in each CCM specimen (Fig. 8A). Slight differences 
in the extent of protein reduction are due to unique tissue composition of each CCM sample. Mean 
values, calculated for CCMs and controls, revealed a FI signal reduction of 62% for occludin, 71% for 
claudin-5 and 74% for ZO-1 in CCM tissue compared to those in control tissue (Fig. 8B). The 
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decrease of fluorescence intensity/protein expression in CCM vessels was found to be highly 
significant in all cases (p < 0.0001, ****). 
Hence, the most striking decrease of protein expression in pathologic vessels was found for GLUT-1 
(78%). Again, reduction was determined as highly significant by an unpaired students t-test (p < 
0.0001, ****). 
 
mRNA expression analysis of occludin, claudin-5, ZO-1 and GLUT-1 in CCMs 
As shown above, protein levels of TJPs occludin, claudin-5, ZO-1 and glucose transporter GLUT-1 
are downregulated at intercellular contact sites and in microvessels of CCMs, respectively. In order to 
validate those findings, we performed real-time RT-PCR and normalized against either endothelial 
marker CD31 (Fig. 9) or vWF (not shown), showing similar results. Total RNAs from eight samples 
were analyzed for each group (CCM and NBT). RNA expression of occludin (13±3.6%), claudin-5 
(25.8±8.3%) and ZO-1 (8.2±3.6%) was significantly decreased in CCM versus to NBT samples 
(Mann-Whitney-Wilcoxon-Test, p < 0.05). Similarly, GLUT-1 was also significantly reduced 
(15.8±4.3) when compared with RNA expression in NBT.  
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Discussion 
 
In this study, we discovered that tight junction proteins occludin, claudin-5, ZO-1, and glucose 
transporter protein GLUT-1 compositions are impaired in CCM tissue. Expression of these proteins 
was strongly reduced at interendothelial contact sites, and appeared negative in most of the vessels.  
In healthy endothelial layers, correct assembly of TJs is essential for the maintenance of a functional 
permeability barrier. It is known, that the structural composition of TJs in ECs of brain capillaries is 
the most complex among any other physiological systems (43). Therefore, it is suggested that an 
impairment of TJ assembly can lead to a loss of BBB integrity (44-46). Furthermore, localization of 
GLUT-1 is considered to be an excellent indicator of a normally functioning BBB (31-33). We 
therefore investigated the expression of TJPs and GLUT-1 to get more information about subcellular 
events leading to an aggressive behavior of a CCM lesion. In fact, occludin and claudin-5, which are 
critical for proper BBB function and permeability (45, 47, 48), are downregulated at interendothelial 
contact sites in CCM tissue. Furthermore, we observed that TJ-associated protein ZO-1 expression 
was also altered. ZO-1 and occludin are considered to be the most important protein components for 
the maintenance of the barrier function of brain microvessels (49-51). Additionally, previous studies 
have found occludin to play an important role in the regulation of brain capillary permeability (52). 
Other studies show that claudin-5 plays an essential role in TJ formation generating the structural and 
functional core of the multiprotein complex (27). Our findings, of deviations in TJP localization, are 
accompanied by clear protein redistribution within the surrounding brain parenchyma of CCM vessels. 
The resulting incorrect assembly of TJs may lead to a malfunction of proper BBB. Moreover, 
downregulation of ZO-1 suggests a disturbance in interaction of TJs with the actin cytoskeleton, 
strongly assuming a direct influence in the pathology of CCMs. This may lead to the possibility of a 
disruption in the cellular architecture, which may consequently lead to decreasing cellular stability. It 
is known, that downregulation of ZO-1 in CCMs results in a mismatch between interacting TJPs. 
Furthermore, overexpression of occludin and inadequate levels of ZO-1 enhance the impairment of the 
BBB (29). Additionally, occludin phosphorylation correlates with TJ formation and regulation of 
junction permeability and interaction with ZO-1 (53-55). As claudin-5 is a key determinant of trans-
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endothelial resistance at the BBB, alterations in its interacting proteins can also lead to a disruption of 
the barrier function (53).  
Taken together, our observations give strong evidence that cell-cell contacts of CCM vessels are 
disorganized to some extent and that TJ proteins are redistributed in parts of the EC surrounding 
tissue. These observations suggest an alteration of tight junction assembly in CCMs leading to a 
malfunctioning permeability barrier, like it is reported in brain tumor vessels or in brain 
microcapillaries after ischemic events (22, 38, 56). And indeed, in many patients, CCM pathology 
comprises repeated microhemorrhages into the surrounding brain parenchyma corresponding to an 
impaired permeability of brain capillaries. Recently, it was shown in a CCM mouse model, that 
heterozygosity at Ccm2 locus impaired endothelial barrier function via alterations in cell-to-cell 
interactions, cytoskeletal architecture and lumen formation (15).  In addition, loss of CCM1 results in 
disruption of junctional stability that leads to increased permeability in vitro and in vivo. It also has 
been shown that the activation of the Rho GTPase RhoA and its downstream effector ROCK, in turn, 
caused by a loss of CCM1 and CCM2, influences vascular leakage (15, 17). Therefore, most likely 
either direct and linker protein mediated interactions between CCM1/CCM2 and TJPs probably exist. 
However, it has to be mentioned, that CCM vessels are not devoid of correctly assembled TJ 
complexes, even though expression was weakened, linear staining patterns of occludin, claudin-5 and 
ZO-1 could still be observed along the endothelial cell-cell contacts in very few CCM foci. Therefore, 
further examinations must be carried out to investigate whether higher percentage of linear TJP 
arrangement at cell-cell-boarders correlates with the aggressive clinical behavior of a lesion, as already 
suggested by other groups (20, 57). 
Quantification of signal intensities of TJP expression confirmed our initial immunohistochemical 
observation. Downregulation of occludin, claudin-5 and ZO-1 in regions of interendothelial contact 
sites has been shown to be highly significant and strongly validates the assumption that TJP are critical 
for the barrier function of brain vasculature and thus disruption of their expression leads to an 
impairment of BBB function.  
We also investigated the expression pattern of GLUT-1 within CCMs, since it was shown that 
alterations of TJP was paralleled by a reduction of GLUT-1 in cerebral endothelial cells and is 
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consistent with BBB opening in tumor tissues (31-33, 38). Furthermore, it is known, that BBB 
breakdown occurs in human CCMs and is, amongst others, thought to be responsible for aggressive 
behavior of a lesion (20, 57). However, an underlying mechanism leading to an expansion and rupture 
of a CCM lesion, remains a mystery (58). As already expected, alterations in TJP distribution was 
accompanied by a massive downregulation of GLUT-1, which is found to be highly significant. This 
effect was accompanied by an irregular fibronectin staining which reflects vessel leakage. In most 
CCM vessels, GLUT-1 is completely absent and with positive signal being detectable in erythrocytes 
only. Staining of red blood cells in extravascular CCM tissue either indicates recent hemorrhage and 
serves as an internal positive control. GLUT-1 is the only known endothelial BBB glucose transporter 
protein, therefore its downregulation is probably correlated to impaired glucose uptake into the brain 
and metabolic rate of cells (59).  
Our analysis revealed that the scarcity of in TJP and GLUT-1 protein levels did correspond to 
modifications in gene expression. Changes in relative amounts of TJP- and GLUT-1-mRNA were 
evaluated as highly significant. Therefore it appears to be obvious that differences in protein 
concentrations at TJs and EC plasma membranes are caused by downregulation of mRNA expression. 
Additionally, to some extent, impaired TJP and GLUT-1 levels in CCM vessels may also correspond 
to protein redistribution within the tissue which could be influenced by alterations with further binding 
partners. In this context, impaired interactions with adherens junction components (AJs) could also 
play a role. The most important element of AJs consists of the VE-Cadherin/-catenin complex (60). It 
is known, that CCM1/Krit1 interacts with -catenin, which in turn shows cross-reaction with TJs, 
probably in a Rap-1 GTPase-dependent manner (21, 61). Therefore it should be taken into account that 
alterations in TJPs and GLUT-1 levels could in turn influence or be caused by impairments in AJ 
protein components. 
In conclusion, our data strongly supports the fundamental role of TJ complexes and TJP in the 
pathogenesis of CCMs. We were able to show that CCM pathology corresponds to an impaired 
localization of occludin, claudin-5 and ZO-1 at interendothelial contact sites, which is accompanied by 
a massive reduction of GLUT-1 in dilated CCM microvessels. These findings may affect vascular 
matrix stability, and thus can contribute to an aggressive clinical behavior seen in CCMs. Future 
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attempts will need to study the interactions of TJPs with CCM1, 2 and 3 gene products and other 
binding partners, for example AJ proteins. Furthermore, more information about the role of TJPs in the 
formation of a tight BBB in CCM will greatly facilitate a better understanding of lesional behavior and 
could be beneficial in the development of an appropriate treatment. 
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Figure Legends 
 
FIGURE 1. Localization of the tight junction protein occludin (green) in CCM specimens: Confocal 
z-series projections of CCM#1, CCM#2 (A-B) and control samples c#2, c#4 (C-D). Occludin is 
distributed in a linear pattern along vessels of control tissues (C’: cross sectional; D’: longitudinal).  
Occludin is redistributed and shows decreased expression in ECs of CCMs (A’: cross sectional; B’: 
longitudinal). The endothelial cell marker protein PECAM-1 (CD31) is stained in red (A’’-D’’). DAPI 
(blue) is shown in A-D and merged images in A’’’-D’’’. Bars: 20 μm.  
 
FIGURE 2. Distribution of TJP claudin-5 (green) and localization of EC-marker CD31 (red: A’’-D’’) 
in CCM specimens: CCM#2, CCM#3 (A-B) and controls: c#2, c#4 (C-D) by confocal microscopy.  
Claudin-5, same as occludin, is distributed linearly in vessels of control tissues (C’: cross sectional; 
D’: longitudinal). In CCM endothelial cells, claudin-5 expression is decreased (A’ and B’: cross 
sectional). DAPI (blue) is shown in A-D and merged images in A’’’-D’’’. Bars: 20 μm. 
 
FIGURE 3. Confocal microscopy images of TJP ZO-1 (green) and CD31 (red) of CCMs (CCM#2, 
CCM#3) and control specimens (c#1, c#4). As in control tissue section stainings for occludin and 
claudin-5, ZO-1 is distributed in a typical linear vessel pattern (C’: cross sectional; D’: longitudinal). 
In contrast, ZO-1 is significantly decreased (A’-B’: cross sectional) in CCM samples. DAPI (blue) is 
mapped in A-D and merged images in A’’’-D’’’. Bars: 20μm. 
 
FIGURE 4. Immunostaining for occludin (green) and collagen IV (red) on two CCM and NBT 
samples, respectively. Different phenotypes of occludin distribution are observed. Similar to control 
vessels, the linear pattern of occludin staining is preserved but thinned (A: longitudinal). To some 
extent, occludin is arranged in a punctate pattern along cell-cell contacts (B: longitudinal). At other 
foci, vessels are completely unstained along the major length of their profile but show isolated, 
residual protein aggregates (C: cross sectional). Occludin is distributed in a linear pattern in 
microvessels of the adult human brain (cerebral cortex) (D and E). Basement membranes of capillaries 
are labeled by collagen IV-antibody (A-E). Nuclear staining with TO-PRO3 (blue) is shown in A-E. 
Bars: A, B and D, E 25 μm; C 10 μm. 
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FIGURE 5. Immunostaining for claudin-5 (green) and collagen IV (red) on two CCM specimens and 
NBT. In most instances, vessels appear negative for claudin-5. At some foci, claudin-5 is diffusely 
distributed within the tissue and not localized to intercellular contact sites (A: cross sectional). Few 
vessels show a punctate staining pattern (B: cross sectional). Decreased claudin-5 staining is seen 
along the EC cell contacts (C: cross sectional). Linear claudin-5 staining in capillaries of control NBT 
(D: longitudinal). Basement membranes of microvessels are labeled by collagen IV-antibody (A-D). 
Nuclear staining with TO-PRO3 (blue) is shown in A-C. Bars: A/D 30 μm; B/C 10 μm.  
 
FIGURE 6. Confocal imaging of cryosections of CCM (CCM#1, CCM#6) and NBT (c#1, c#5) 
immunostained for GLUT-1 (green) and CD31 (red). In control vessels, GLUT-1 is distributed 
uniformly (C’: cross/longitudinal; D’: longitudinal). However, the glucose transporter 1 is massively 
downregulated in CCM tissue samples (A’: cross sectional; B’: cross/longitudinal). DAPI (blue) is 
mapped in A-D and merged images in A’’’-D’’’. Bars: 20μm. 
 
FIGURE 7. Localization of fibronectin (green) and collagen VI as EC-marker (red: A’’-B’’) in CCM 
specimens: CCM#5 (A) and control: c#1 (B) by confocal microscopy. In vessels of the control tissue,  
fibronectin is distributed regularly (B’: cross sectional). In CCM endothelial cells, fibronectin 
expression is impaired and irregular (A’: cross sectional). DAPI (blue) is shown in A+B and merged 
images in A’’’+B’’’. Bars: 20 μm. 
 
FIGURE 8. Analysis of FI of occludin, claudin-5, ZO-1 and GLUT-1 stainings in cryosections of 
CCMs and control tissues. Experiments were done in triplicates. (A) MFI of each CCM and control 
specimen; (B) MFI (in %) of the seven normalized CCM specimens versus controls. Mean control 
MFI was calculated as 100% (mean ± standard error of mean). Changes in MFI were calculated as 
highly significant for all proteins examined (students t-test, p < 0.0001, ****). 
 
FIGURE 9. Relative mRNA expression of occludin, claudin-5, ZO-1 and GLUT-1 in CCM and NBT. 
Data is shown as mean values ± SEM of two individual experiments with eight samples in each group. 
Data were normalized against the EC-marker gene CD31. mRNA expression levels from NBT (n=8) 
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are set to as 100% (mean  standard error of the mean). Differences in mRNA concentrations were 
determined by the Mann-Whitney-Wilcoxon test with p < 0.05 being considered statistically 
significant.   
 
Legends to supplementary figures 
 
FIGURE S1. Confocal imaging of paraffin sections of CCM (CCM#1) and NBT (c#1) 
immunostained for occludin (green) and vWF (red). In control vessels, occludin is distributed in a 
linear pattern (C’: cross sectional; D’: longitudinal). However, occludin is massively downregulated in 
CCM tissue samples (A’ and B’: cross sectional). DAPI (blue) is mapped in A-D and merged images 
in A’’’-D’’’. Bars: 20μm. 
 
FIGURE S2. Immunostaining for GLUT-1 (green) and vWF (red) in paraffin embedded CCM and 
NBT specimens (CCM3; c1). Decreased or absent GLUT-1 staining is seen in vessels of CCM 
tissue (A’ and B’: cross sectional). In capillaries of control NBT, GLUT-1 is distributed uniformly 
(C’: cross sectional; D’: longitudinal). ECs are labelled against the marker protein vWF (A’’-D’’). 
Nuclear staining with DAPI (blue) is shown in A-D. Bars: 20 μm.  
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Abstract 
 
Cerebral cavernous malformations (CCMs) often cause hemorrhages which can result in severe 
symptoms like hemiparesis or seizures. The underlying mechanism behind the aggressive behavior of 
a CCM lesion is undetermined to date, but alterations of vascular matrix components may be 
responsible. Hence, we investigated the localization of the tight junction proteins (TJPs) occludin, 
claudin-5 and ZO-1 within endothelial cells. Additionally, we examined the expression of glucose 
transporter 1 (GLUT-1) which is sensitive to alterations in TJP levels. Seven CCM and five control 
(normal brain tissue) specimens were examined by fluorescent immunohistochemistry for occludin, 
claudin-5, ZO-1 and GLUT-1. Our pProtein expression analysis showed that occludin, claudin-5 and 
ZO-1 were downregulated at intercellular contact sites and partly redistributed within the surrounding 
tissue in all patients examined. We also observed a massive reduction of GLUT-1 that was not 
observed in any of the control specimens.and Ccorresponding analysismRNA levels were quantified 
using quantitative real-time RT-PCR (qRT-PCR), revealed a and analyzed using appropriate software 
and microarray analysis, respectivelysignificant downregulation in mRNA-expression of occludin, 
claudin-5, ZO-1 and GLUT-1. Here we show that occludin, claudin-5 and ZO-1 are downregulated at 
intercellular contact sites and partly redistributed within the surrounding tissue in all patients 
examined. These findings are accompanied by a massive reduction of GLUT-1 that was not observed 
in any of the control specimens. In contrast, only ZO-1 mRNA is significantly downregulated in CCM 
tissue suggesting a crucial role in proper TJ assembly.  
 
 
Keywords: cerebral cavernous malformation, tight junctions, occludin, claudin-5, ZO-1, GLUT-
1 
 3 
Introduction 
 
Cerebral cavernous malformations and arteriovenous malformations (AVMs) present the most 
common lesion subtypes of vascular malformations of the brain (VMBs), affecting more than 0.5% of 
the population (1-4). CCMs are composed of dilated, blood filled capillary clusters lined by 
endothelium, lacking intervening brain parenchyma. Due to the expression of angiogenic factors, they 
reflect more a developing rather than a mature vessel phenotype (1, 3, 5-7). Cavernous malformations 
occur sporadically, as a single lesion, or as an inherited, autosomal dominant form with multiple 
lesions (8). To date, mutations in three genes have been identified to cause the familial form of the 
disease: CCM1/KRIT1, CCM2/MGC4607 and CCM3/PDCD10 (9). It has been hypothesized that a 
second hit in the somatic allele is necessary to cause CCM formation. Indeed, in 2005, a biallelic 
CCM1 somatic and germ line mutation has been shown in a surgically excised human lesion for the 
first time (10). In the meantime, biallelic mutations were also reported for CCM2 and CCM3 (11). 
Furthermore, transgenic mice heterozygous for Ccm1, only develop CCM lesions when they exhibit an 
additional homozygous knockout of the tumor suppressor gene Trp53 (ccm1
+/-
 Trp53
-/-
). Similarly, 
heterozygous mice with Ccm2
±
 only form CCM lesions when sensitized by a second hit (12, 13). This 
further supports the hypothesis of a second genetic somatic mutation in CCMs.  
Recently, it was shown that CCM1 represents an antiangiogenic protein and that gene mutations in  
KRIT1 correlate with excessive capillary sprouting, which is characteristic for human CCM pathology 
(7). PTEN promoter methylation, HEG transmembrane receptor expression, RhoA GTPase and ROCK 
activation are involved in the pathogenesis (14-17) and therefore have also been suggested to 
contribute to the mechanism of lesion formation.  
Endothelial cells (ECs) are the major component of vessel walls. It is thought that they play a central 
role in the clinical behavior of a cerebral vascular malformation showing abnormal ultrastructural 
pathological features (18). The thin walls of CCM vessels possess limited number of intact 
interendothelial tight junctions, which may contribute to the known propensity of recurrent 
microhemorrhage seen in CCMs (19). There is growing evidence that an impairment of the blood-
brain barrier (BBB) correlates with a decrease of tight junctions in the endothelial layer and 
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furthermore that CCM1 as well as CCM2 could play a junction stabilizing role (15, 17, 20, 21). 
Recently, it was shown TJP occludin to be involved in intercellular gap formation reflecting BBB 
breakdown in porcine brain capillary endothelial cells (22).  
Tight junctions are located at the lateral apical side of the cell membrane in regions of close cell–cell 
contacts, e.g. in the cerebral microcapillary endothelium. They turn cell-to-cell contacts into zones of 
tight adherence thereby inhibiting the paracellular pathway for drugs or solutes from plasma into the 
central nervous system (CNS) (23). Different integral membrane proteins, associated cytoplasmatic 
proteins and extracellular matrix components are involved in the proper assembly of tight junction 
complexes (24). Two junctional core proteins, occludin and claudin-5 play a key role in BBB integrity 
in the microvascular endothelium. Both consist of four transmembrane domains, intracellular N- and 
C-termini, and two extracellular domains that might interact with cell membranes of vicinal cells thus 
sealing the intercellular clefts (22, 25, 26). Different gain-of-function and loss-of-function experiments 
reveal that claudin-5 is involved in the structure of TJ strands and cell adhesion, whereas occludin 
probably has some accessory functions (27). Furthermore, adaptor/scaffold proteins such as zonula 
occludens (ZO-1, ZO-2 and ZO-3) connect TJ-associated integral membrane proteins to the actin 
cytoskeleton and other structural proteins. The first reported linker protein, ZO-1 directly interacts 
with occludin and claudins and is essential for TJ formation (27, 28). It was hypothesized that the 
interaction of occludin with ZO-1 modulates its function in sealing the junction, since paracellular 
permeability increases when an imbalance occurs between occludin and ZO-1 molecules (29, 30). 
The localization of glucose transporter 1 (GLUT-l) in ECs of microvessels is considered as an 
indicator of a functioning BBB (31-33). The protein is widely expressed in adult tissues, but it is most 
abundant in fibroblasts, erythrocytes and endothelial cells with low levels of expression in muscle, 
liver and adipose tissue (34-36). In healthy brain endothelium, TJ sealing of the interendothelial clefts 
is linked to the expression of GLUT-1. Alterations in transporter protein expression are directly related 
to an increased permeability of endothelial layers in the brain and also linked to alterations in TJ 
properties  (31-33). 
To date, the role of TJs and their core proteins occludin and claudin-5 are not fully understood in the 
context of CCM lesions. But there is growing evidence that vascular development and endothelial 
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permeability are dysregulated (37). In brain tumor pathology it was shown, that decreased expression 
of GLUT-1 is coupled to alterations in TJP expression levels and consequently BBB opening (38). 
Therefore, we analyzed the expression of TJPs (occludin, claudin-5 and ZO-1) and the transporter 
protein GLUT-1 by classical immunohistochemistry and confocal fluorescent microscopy on cryo- 
and vibratomeparaffin-sections of seven CCM specimens and five control samples (normal brain 
tissue; NBT). NBT specimens were received from temporal lobe biopsy during selective 
amygdalohippocampectomy from patients with temporal lobe epilepsy (TLE). Mean fluorescence 
intensity was further quantified. Furthermore, Microarray analysisqRT-PCR was also performed to 
compare gene mRNA expression levels of TJPs and GLUT-1 between in eight CCM and versus eight 
control samples.  
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Materials and Methods 
 
Patients and tissue specimens 
Seven Twelve CCM specimens were obtained from patients undergoing neurosurgical resection. Five 
Thirteen human control tissue specimens (NBT) were received from temporal lobe biopsy during 
selective amygdalohippocampectomy from patients with TLE. The median age of the five seven 
female and two five male patients was 389 (range 237 to 52 years). The clinical data of the seven 
twelve CCM patients is summarized in Table 21. List of patients included in this study is based on the 
consensus recommendations for minimal reporting variables in CCM clinical research (39-41). 
Indication The decision for surgical resectionery was performed made based on after computed 
tomography scan and magnetic resonance imaging. Tissue specimens were immediately transferred to 
the laboratory on ice and divided for snap-frozen preparation and in vitro cell cultureexperiments. 
Samples were snap-frozen in liquid nitrogen (NO2) and embedded in TissueTek O.C.T (Satura Finetek 
Europe, Zoeterwoude, Netherlands) before analysis. Additionally, histological diagnosis was obtained 
by routine clinical neuropathological examination and classified according to the World Health 
Organization standards (Institute of Neuropathology, University Hospital Zurich, Switzerland).  
 
Immunofluorescence, laser scanning confocal microscopy and fluorescence microscopy analysis  
Immunofluorescence analysis was done by threewo different protocols. First, 6 μm cryosections were 
cut with a Leica cryostat, mounted on Superfrost
®
Plus slides (Menzel-Glaser, Braunschweig, 
Germany), fixed with acetone p.aA. for 10 min at room temperature (RT) and stored at -80°C till 
further use. For analysis, slides were acetone-fixed for 5 min at RT and air-dried. Sections were 
incubated with 3% peroxide to quench endogenous peroxidase activity and washed with PBS (pH 7.4). 
Unspecific binding sites were blocked with blocking solution (Candor, Weiβensberg, Germany) for 25 
min at RT. For indirect immunofluorescence, polyclonal rabbit anti-human claudin-5-antibody (5 
μg/ml; Abcam, Cambridge, UK), polyclonal monoclonal mouserabbit anti-human occludin-antibody 
(4 μg/ml; Invitrogen, Carlsbad, CA CA, USA), monoclonal mouse anti-human GLUT-1-antibody (1 
μg/ml; Abcam, Cambridge, UK), monoclonal mouse anti-human fibronectin (2 µg/ml; Abcam, 
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Cambridge, UK), mouse monoclonal anti-human CD31 (10μg/ml; DAKO, Glostrup, DK), monoclonal 
rabbit anti-human CD31 (1:40; epitomics, Burlingame, CA, USA),  and monoclonal mouse anti-
human collagen-IV-antibody (2 μg/ml; DAKO, Glostrup, DK) and polyclonal rabbit anti-human 
collagen-VI-antibody (2 µg/ml; Abcam, Cambridge, UK) were incubated at 37°C for 1h. Appropriate 
secondary antibodies, ALEXA 488-conjugated (goat anti-rabbit and goat anti-mouse 1:100, 
Invitrogen, Carlsbad, CA, USA) or ALEXA 594-conjugated secondary antibody antibody (goat anti-
rabbit and goat anti-mouse, 1:100, Invitrogen Carlsbad, CA, USA) were incubated for 25 min at RT. 
All antibodies were diluted in “Antikörper-VerdünnungspufferAntibody Dilution Buffer” (DCS, 
Hamburg, Germany). Between each step, the sections were washed in PBS three times 5 min each. 
Control stainingss included the isotype matched primary monoclonal antibodies. In all cases, the 
results of the each negative controls confirmed the specificity of the corresponding antibody staining. 
Specimens were mounted in fluorescent mounting medium (DAKO, Glostrup, DK) and sections were 
viewed on a Leica TCS SP5 (Leica, Wetzlar, Germany) confocal laser scanning microscope (CLSM) 
using 63x and 100x objectives. Confocal images were taken at 1-2 μm intervals through the z-axis of 
the section. Projection images formed by serial optical planes were analyzed, digitally recorded, and 
stored as tagged image file fFormat files using Adobe Photoshop CS3 software (Adobe Systems, San 
Jose, CA, USA). Second, tissue samples were placed into 4% neutral buffered formalin for twelve 
hours, and then were processed routinely for paraffin inclusion. Sections were obtained at 4 µm 
intervals using a Microm rotary microtome (Leica, Wetzlar, Germany), put in water and mounted to 
Superfrost
®
Plus slides (Menzel-Glaser, Braunschweig, Germany). After rehydration, for antigen 
retrieval, sections were boiled in a microwave oven in 0.01M citrate buffer solution (pH 6) for 20 
minutes. Endogenous peroxidase was inactivated with 3% hydrogen peroxide and nonspecific 
antigenic sites were blocked with blocking solution (Candor, Weißensberg, Germany) for 25 minutes 
at RT. As already described above, sections were incubated with primary occludin- (4 µg/ml, 
Invitrogen, Carlsbad, CA, USA), GLUT-1- (1 μg/ml; Abcam, Cambridge, UK) and polyclonal rabbit 
anti-human vWF-antibodies (28.5 µg/ml; DAKO, Glostrup, DK) followed by incubation with 
appropriate secondary antibodies, ALEXA 488-conjugated (goat anti-mouse 1:100, Invitrogen, 
Carlsbad, CA, USA) or ALEXA 594-conjugated secondary antibody antibody (goat anti-rabbit, 1:100, 
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Invitrogen, Carlsbad, CA, USA). Third, tissue specimens were fixed for 3 h at 4°C by immersion in 
2% paraformaldehyde plus 0.2% glutaraldehyde solution and washed in PBS (pH 7.6). The blocks of 
tissue were sectioned at 20 μm thickness using a vibrating microtome (Leica, Wetzlar, Germany 
Microsystem; Milan, Italy) and sections were collected on polylysine slides (Menzel-Glaser, 
Braunschweig, Germnay, GmbH). Heat-mediated antigen retrieval was achieved by microwave pre-
treatment in 0.01 M citrate buffer (pH 6.0) for 15 min at 750W. Sections were incubated with 
PBS/0.5% Triton X-100 for 30 min, blocked with protein block serum free (DAKO, Glostrup, DK) for 
15 min at RT and incubated overnight at 4 °C with primary antibodies at various dilutions: mouse 
monoclonal anti-human claudin-5 (1:20; Zymed Laboratories, Invitrogen, Carlsbad, CA, USA), rabbit 
polyclonal anti-human occludin (1:50; Zymed Laboratories, Invitrogen, Carlsbad, CA, USA), rabbit 
polyclonal anti-human collagen IV (1:200; Acris Antibodies GmbH, Hiddenhausen, Germany), mouse 
monoclonal anti-human collagen IV (1:50; DAKO, Glostrup, DK) and mouse monoclonal anti-human 
CD31 (1:50; DAKO, Glostrup, DK). A mixture of biotinylated horse anti-mouse (1:400; Vector, 
Vector Laboratories, Inc.; Burlingame, CA, USA) or biotinylated goat anti-rabbit IgG (1:400; Vector, 
Vector Laboratories, Inc.; Burlingame, CA, USA) and Alexa568-conjugated goat anti-rabbit (1:400, 
Invitrogen, Carlsbad, CA, USA) or Alexa555-conjugated goat anti-mouse IgG (1:400, Invitrogen, 
Carlsbad, CA, USA) were incubated as secondary antibodies for 40 min at RT. Streptavidin Alexa 
Fuor 488-conjugated (1:400; Invitrogen, Carlsbad, CA, USA) was used for staining of claudin-5 and 
occludin. The slices were counterstained with TO-PRO-3 (1:10.000 in PBS; Invitrogen, Carlsbad, CA, 
USA) and finally mounted with Vectashield (Vector Vector Laboratories, Inc.; Burlingame, CA, USA) 
and sealed with nail varnish. The stainings were examined under the Leica TCS SP5 confocal laser 
scanning microscope (Leica, Wetzlar, Germany Microsystems) using a sequential scan procedure 
during image acquisition of double-labeled sections. Confocal images were taken at 250-500 nm 
intervals through the z-axis of the sections. Images from individual optical planes and image 
projections of stacks of serial optical planes were analyzed by Leica confocal software (Multicolor 
Package; Leica, Wetzlar, Germany Microsystems). 
 
Image Acquisition, image processing and data analysis  
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Digital image processing for the detection and quantification of fluorescent intensitiy (QFI) in human 
CCM and control samples was performed with a conventional light microscope (Axiovert 100, Zeiss, 
Jena, Germany), a digital microscope camera (AxioCam ICm, Zeiss, Jena, Germany) and the 
AxioVision 4.8 software (Zeiss, Jena, Germany). Fluorescence quantification was sub-divided into 
image acquisition, image preprocessing, and data processing steps (42). All parameters used in the 
acquisition were standardized (detector gain, exposure time) to maintain high reproducibility. Image 
processing of each specimen was provided through region of interest (ROI) analysis. The software 
allows the interactive definition of areas for size and intensity measurements. For data analysis, 
fluorescence intensity/ROI values were obtained for five ROIs/specimen (10 μm2 each). Statistical 
analysis describing the distribution of the intensity of the fluorescence signals was performed to obtain 
graphical representations. 
 
Quantitative RT-PCR analysis 
Differential gene expression levels of claudin-5, occludin, ZO-1 and GLUT-1 were determined by q 
RT-PCR. Therefore, total RNA was isolated from each cavernoma and control tissue sample using the 
RNeasy Mini Kit Isolation System according to the manufactor’s protocol for RNA extraction (Qiagen 
Ltd., Hombrechtikon, Schweiz). 0.5 µg total mRNA of each sample was reverse transcribed to cDNA 
using the High Capacity cDNA Reverse Transcription Kit (ABI, Carlsbad, CA, USA). cDNA was 
used for qRT-PCR with SYBR
®
 Green PCR Master Mix (ABI, Carlsbad, CA, USA) and specific 
primer pairs on a 7900HT Fast Real-Time PCR System with SDS Software v2.4 (ABI, Carlsbad, CA, 
USA). Expression was normalized against the endothelial marker CD31 or vWF. Specific primers 
were designed with the Primer Express 3.0 software (ABI, Carlsbad, CA, USA) and are listed in Table 
1.   
 Gene expression analysis 
 
Differential expression of occludin, claudin-5, ZO-1 and GLUT-1 genes was analyzed by microarray 
as previously described in Shenkar et al. (43). A total of 9 specimens including 6 CCMs (CCM#10-15) 
and 3 normal vessels (superficial temporal arteries (STAs), STA#1-3) were obtained from patients 
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between 2000 and 2003 and the study was approved by the IRB of the University of 
Colorado (COMIRB). The median age of the five female and one male patient was 28 (range 9 to 40 
years). The relevant clinical and lesion features of the cases are listed in Table 2.  
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Statistical analysis 
For quantification and statistical analysis of protein expression levels, experiments were done in 
triplicates analyzing five ROIs/specimen (10μm2) for each patient. Mean fluorescence intensity (MFI) 
values were calculated and averaged. ROIs were selected randomly by criteria that only fluorescent 
signals of vessel wall structures were measured for their intensity. The statistical analysis, using the 
mean fluorescence intensity values of each patient, was performed with Microsoft Excel and 
GraphPad Prism software (version 5 for Windows). To assess whether two independent samples of 
observations come from the same distribution, an unpaired students t-test was used. P-values < 0.01 
were considered as statistically significant. 
mRNA expression levels of each gene were obtained via correction for endothelial density. The results 
are expressed as means ± standard error (SEM). Statistical evaluation was performed with GraphPad 
Prism software (version 5 for Windows). Statistical significance was determined by Mann-Whitney-
Wilcoxon Test . Therefore, values (CCM versus STA) were calculated by dividing the expression 
level of genes of interest (TJPs and GLUT-1) by the expression levels of the EC marker protein 
CD105 (endoglin). Subsequently, values were normalized on the particular mean value of STA 
specimens. P-values < 0.05 were considered as statistically significant. 
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Results 
 
Comparison of TJPs between CCM and NBT microvessels 
Initially, protein expression patterns of TJPs occludin, claudin-5 and ZO-1 from seven CCM and five 
control specimens were examined on intact vascular structures by fluorescent immunohistochemistry 
and analyzed via laser scanning confocal microscopy (representative images of following samples are 
shown: Fig. 1: CCM#1, CCM#2, c#2 and c#4; Fig. 2: CCM#2,CCM#3, c#2 and c#4; Fig. 3: CCM#2, 
CCM#3, c#1 and c#4 and Fig. S1: CCM#1, c#1 and Fig. 4: CCM#1, CCM#6, c#1 and c#5). The levels 
of the TJP expressions were compared to control tissues obtained from patients with temporal lobe 
epilepsy who had undergone surgery. Representative results for two CCM and control specimens, 
respectively, are shown in Ffigs. 1-3 and S14. To identify endothelial cells (ECs), sections were co-
stained for the EC marker protein PECAM-1/CD31 on cryosections (Fig.1-34: A’’-D’’ and A’’’-D’’’) 
and von Willebrand factor (vWF) on paraffin sections (Fig. S1: A’’-D’’). In the endothelial layers of 
CCM tissue, Pprotein expression of occludin, claudin-5 and ZO-1 was clearly decreased in endothelial 
layers of CCM tissue , compared to control brain microvessels, which showed a typical linear staining 
pattern at distinct endothelial cell borders. The linear junctional labeling was either discontinuous or 
amorphous and many vessels even appeared negative for TJPs. In several cases, redistribution of 
proteins was observed in the endothelial layer as well as the surrounding tissue (Fig. 1-3: A’-C’). Co-
staining for CD31 and vWF additionally revealed that only microvessels were analyzed for 
impairment in TJP localization.   
We then proceeded to build three dimensional reconstructions of vascular structures to validate the 
immunofluorescence experiments which showed different localization patterns for TJPs along the 
margin of cell–cell contacts and in the surrounding tissue of CCMs when compared to controls (Fig. 
45 and 56). In CCM tissue, in regions where a protein signal could be determined, few vessels showed 
a punctuate labelling for claudin-5 (Fig. 4B/C and 56A/B), in others occludin and claudin-5 were 
linearly arranged along the endothelial cell-cell contacts as it was observed in the vessels of control 
tissues (Fig. 45A; Fig. 56C). In those cases, the fluorescence signal of both proteins was clearly 
weakened compared to the signal intensity in healthy tissue. Furthermore, in vessels of control tissues, 
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occludin and claudin-5 staining was limited to the vascular intima (Fig. 45D/E and 56D), whereas it 
could also be detected in the surrounding tissue in some regions of the CCM sections (Fig. 56A). 
 
GLUT-1 expression in CCM vessels 
Alterations in transporter protein expression are directly related to an increased permeability of 
endothelial layers in the brain and also linked to alterations in TJ properties (31-33).  
To investigate BBB permeability, which not only corresponds to alterations in TJPs but to an 
impairment of GLUT-1 expression, we also stained CCM and control tissue cryosections for thise 
transmembrane transporter protein (shown in Fig. 6 for samples: CCM#1, CCM#6, c#1 and c#5 on 
cryosections and Fig. S2: CCM#3, c#1 on paraffin embedded sections). We could observe that 
microvessels of control brain tissues were stained uniformly and showed a high level of GLUT-1 
expression (Fig. 6 and S2: 4C’-D’). Unlike in controls, GLUT-1 expression was reduced or 
altogehterabsent in CCM specimens (Fig. 6 and S2: 4A’-B’).  As an internal positive control, 
erythrocytes were stained in every sample, to reflect membranous GLUT-1 activity (Fig. 6 and S2: 
B’). To conclude, linear TJP localization at EC boarders was clearly disrupted and accompanied by a 
massive reduction of GLUT-1 staining. This reflects an impairment of the BBB, which is supported by 
vessel leakage illustrated in Fig. 7 by an irregular fibronectin staining around CCM microvessels. As 
an internal positive control, erythrocytes were stained in every sample, to reflect membranous GLUT-
1 activity (Fig. 4B’’-C’’). 
 
Alterations in TJP and GLUT-1 expression in CCMs 
For further analysis, alterations in protein expression levels were quantified by determining signal 
intensities of immunofluorescent labeled cryosections of CCM against the intensities in control 
specimens. As described above, a strong reduction of TJP and glucose transporter proteinGLUT-1 
levels were observed along EC cell borders, corresponding to decreased FI per ROI (Fig. 87). A drop 
of occludin-, claudin-5-, ZO-1- and GLUT-1-fluorescence signal was determined in each CCM 
specimen (Fig. 87A). Slight differences in the extent of protein reduction are due to unique tissue 
composition of each CCM sample. Mean values, calculated for CCMs and controls, revealed a FI 
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signal reduction of 62% for occludin, 71% for claudin-5 and 74% for ZO-1 in CCM tissue compared 
to those in control tissue (Fig. 87B). The decrease of fluorescence intensity/protein expression in CCM 
vessels was found to be highly significant in all cases (p < 0.0001, ****). 
Hence, the most striking decrease of protein expression in pathologic vessels was found for GLUT-1 
(78%). Again, reduction was determined as highly significant by an unpaired students t-test (p < 
0.0001, ****). 
 
mRNA expression Microarray analysis of TJP occludin, claudin-5, ZO-1 and GLUT-1 gene 
expression between in CCMs and STAs 
As shown above, protein levels of TJPs occludin, claudin-5, ZO-1 and glucose transporter GLUT-1 
are downregulated at intercellular contact sites and in microvessels of CCMs, respectively. In order to 
validate those findings, we performed real-time RT-PCR and normalized against either endothelial 
marker CD31 (Fig. 9) or vWF (not shown), showing similar results. TTotal RNAs from eightsix 
samples were analyzed for each group (CCM and three NBT)STA samples were analyzed using a 
gene discovery approach and the confirmation of known gene methodologies described in Shenkar et 
al. (43).  In our study, TJ and GLUT-1 protein levels were found to be downregulated at intercellular 
contact sites and in microvessel plasma membranes, respectively, in CCM specimens. Thus, 
microarray analysis was performed to determine relative mRNA expression levels for the genes of 
interest. Subsequently, values were divided by the mean of relative mRNA expression levels of the EC 
marker genes CD31 (PECAM-1), CD105 (endoglin), CD146 (MCAM) and Von Willebrand factor 
(vWF) (Fig. 8). This was done to correct variations in tissue compositions (EC density) among 
specimens. Interestingly, relative amounts of occludin, claudin-5, ZO-1 and GLUT-1 mRNA were not 
significantly altered in CCM samples compared to STAs (students t-test, p > 0.05)RN. A expression of 
occludin (13±3.6%), claudin-5 (25.8±8.3%) and ZO-1 (8.2±3.6%) was significantly decreased in CCM 
versus to NBT samples (Mann-Whitney-Wilcoxon-Test, p < 0.05)There was a slight trend for an 
increase in occludin (p = 0.1846) and claudin-5 (p = 0.2133) gene expression levels in CCMs. 
Moreover, weaker tendency of ZO-1 gene expression was observed in CCMs compared to levels in 
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STAs (p = 0.1896). Finally, no alterations in GLUT-1 mRNA levels were found in CCMs versus 
controls (p = 0.8264).  
.  
Similarly, GLUT-1 was also significantly reduced (15.8±4.3) when compared with RNA 
expression in NBT.  
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Discussion 
 
In this study, we discovered that tight junction proteins occludin, claudin-5, ZO-1, and glucose 
transporter protein GLUT-1 compositions are impaired in CCM tissue. Expression of these proteins 
was strongly reduced at interendothelial contact sites, and appeared negative in most of the vessels.  
In healthy endothelial layers, correct assembly of TJs is essential for the mainteainance of a functional 
permeability barrier. It is known, that the structural composition of TJs in ECs of brain capillaries is 
the most complex among any other physiological systems (43). Therefore, it is suggested that an 
impairment of TJ assembly can lead to a loss of BBB integrity (44-46). Furthermore, localization of 
GLUT-1 is considered to be an excellent indicator of a normally functioning BBB (31-33). We 
therefore investigated the expression of TJPs and GLUT-1 to get more information about subcellular 
events leading to an aggressive behavior of a CCM lesion. In fact, occludin and claudin-5, which are 
critical for proper BBB function and permeability (45, 47, 48), are downregulated at interendothelial 
contact sites in CCM tissue. Furthermore, we observed that TJ-associated protein ZO-1 expression 
was also altered. ZO-1 and occludin are considered to be the most important protein components for 
the maintenance of the barrier function of brain microvessels (49-51). Additionally, previous studies 
have found occludin to play an important role in the regulation of brain capillary permeability (52). 
Other studies show that claudin-5 plays an essential role in TJ formation generating the structural and 
functional core of the multiprotein complex (27). Our findings, of deviations in TJP localization, are 
accompanied by clear protein redistribution within the surrounding brain parenchyma of CCM vessels. 
The resulting incorrect assembly of TJs may lead to a malfunction of proper BBB. Moreover, 
downregulation of ZO-1 suggests a disturbance in interaction of TJs with the actin cytoskeleton, 
strongly assuming a direct influence in the pathology of CCMs. This may lead to the possibility of a 
disruption in the cellular architecture, which may consequently lead to decreasing cellular stability. It 
is known, that downregulation of ZO-1 in CCMs results in a mismatch between interacting TJPs. 
Furthermore, overexpression of occludin and inadequate levels of ZO-1 enhance the impairment of the 
BBB (29). Additionally, occludin phosphorylation correlates with TJ formation and regulation of 
junction permeability and interaction with ZO-1 (53-55). As claudin-5 is a key determinant of trans-
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endothelial resistance at the BBB, alterations in its interacting proteins can also lead to a disruption of 
the barrier function (53).  
Taken together, our observations give strong evidence that cell-cell contacts of CCM vessels are 
disorganized to some extent and that TJ proteins are redistributed in parts of the EC surrounding 
tissue. These observations suggest an alteration of tight junction assembly in CCMs leading to a 
malfunctioning permeability barrier, like it is reported in brain tumor vessels or in brain 
microcapillaries after ischemic events (22, 38, 56). And indeed, in many patients, CCM pathology 
comprises repeated microhemorrhages into the surrounding brain parenchyma corresponding to an 
impaired permeability of brain capillaries. Recently, it was shown in a CCM mouse model, that 
heterozygosity at Ccm2 locus impaired endothelial barrier function via alterations in cell-to-cell 
interactions, cytoskeletal architecture and lumen formation (15).  In addition, loss of CCM1 results in 
disruption of junctional stability that leads to increased permeability in vitro and in vivo. It also has 
been shown that the activation of the Rho GTPase RhoA and its downstream effector ROCK, in turn, 
caused by a loss of CCM1 and CCM2, influences vascular leakage (15, 17). Therefore, most likely 
either direct and linker protein mediated interactions between CCM1/CCM2 and TJPs probably exist. 
However, it has to be mentioned, that CCM vessels are not devoid of correctly assembled TJ 
complexes, even though expression was weakened, linear staining patterns of occludin, claudin-5 and 
ZO-1 could still be observed along the endothelial cell-cell contacts in very few CCM foci. Therefore, 
further examinations must be carried out to investigate whether higher percentage of linear TJP 
arrangement at cell-cell-boarders correlates with the aggressive clinical behavior of a lesion, as already 
suggested by other groups (20, 57). 
Quantification of signal intensities of TJP expression confirmed our initial immunohistochemical 
observation. Downregulation of occludin, claudin-5 and ZO-1 in regions of interendothelial contact 
sites has been shown to be highly significant and strongly validates the assumption that TJP are critical 
for the barrier function of brain vasculature and thus disruption of their expression leads to an 
impairment of BBB function.  
We also investigated the expression pattern of GLUT-1 within CCMs, since it was shown that 
alterations of TJP was paralleled by a reduction of GLUT-1 in cerebral endothelial cells and is 
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consistent with BBB opening in tumor tissues (31-33, 38). Furthermore, it is known, that BBB 
breakdown occurs in human CCMs and is, amongst others, thought to be responsible for an aggressive 
behavior of a lesion (20, 57). However, an underlying mechanism leading to an expansion and rupture 
of a CCM lesion, remains a mystery (58). As already expected, alterations in TJP distribution was 
accompanied by a massive downregulation of GLUT-1, which is found to be highly significant. This 
effect was accompanied by an irregular fibronectin staining which reflects vessel leakage. In most 
CCM vessels, GLUT-1 is completely absent and with positive signal being detectable in erythrocytes 
only. Staining of red blood cells in extravascular CCM tissue either indicates recent hemorrhage and 
serves as an internal positive control. GLUT-1 is the only known endothelial BBB glucose transporter 
protein, therefore its downregulation is probably correlated to impaired glucose uptake into the brain 
and metabolic rate of cells (59).  
Our analysis revealed that alterations the scarcity of in TJP and GLUT-1 protein distribution levels did 
not correspond to modifications in gene expression. Changes in relative amounts of TJP- and GLUT-
1-mRNA were evaluated as  nothighly statistically significant. Therefore it appears to be obvious that 
differences in protein concentrations at TJs and EC plasma membranes are caused by downregulation 
of mRNA expression. Additionally, to some extent, impaired  posttranscriptional and posttranslational 
events, respectively. It also substantiates suspicion that impaired alterations in TJP and GLUT-1 levels 
in CCM vessels may also correspond to protein redistribution within the tissue which could be 
influenced by alterations with further binding partners. In this context, impaired interactions with 
adherens junction components (AJs) could also play a role. The most important element of AJs 
consists of the VE-Cadherin/-catenin complex (60). It is known, that CCM1/Krit1 interacts with -
catenin, which in turn shows cross-reaction with TJs, probably in a Rap-1 GTPase-dependent manner 
(21, 61). Therefore it should be taken into account that alterations in TJPs and GLUT-1 levels could in 
turn influence or be caused by impairments in AJ protein components. 
, instead of downregulation at absolute protein expression levels. 
In conclusion, our data strongly supports the fundamental role of TJ complexes and TJP in the 
pathogenesis of CCMs. We were able to show that CCM pathology corresponds to an impaired 
localization of occludin, claudin-5 and ZO-1 at interendothelial contact sites, which is accompanied by 
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a massive reduction of GLUT-1 in dilated CCM microvessels. These findings may affect vascular 
matrix stability, and thus can contribute to an aggressive clinical behavior seen in CCMs. Future 
attempts will need to study the interactions of TJPs with CCM1, 2 and 3 gene products and other 
binding partners, for example AJ proteins. Furthermore, more information about the role of TJPs in the 
formation of a tight BBB in CCM will greatly facilitate a better understanding of lesional behavior and 
could be beneficial in the development of an appropriate treatment. 
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Figure Legends 
 
FIGURE 1. Localization of the tight junction protein occludin (green) in CCM specimens: Confocal 
z-series projections of CCM#1, CCM#2 (A-B) and control samples c#2, c#4 (C-D). Occludin is 
distributed in a linear pattern along vessels of control tissues (C’: cross sectional; D’: longitudinal).  
Occludin is redistributed and shows decreased expression in ECs of CCMs (A’: cross sectional; B’: 
longitudinal). The endothelial cell marker protein PECAM-1 (CD31) is stained in red (A’’-D’’). DAPI 
(blue) is shown in A-D and merged images in A’’’-D’’’. Bars: 20 μm.  
 
FIGURE 2. Distribution of TJP claudin-5 (green) and localization of EC-marker CD31 (red: A’’-D’’) 
in CCM specimens: CCM#2, CCM#3 (A-B) and controls: c#2, c#4 (C-D) by confocal microscopy. 
Lik e occludin, claudinClaudin-5, same as occludin, is distributed linearly in vessels of control tissues 
(C’: cross sectional; D’: longitudinal). In CCM endothelial cells, claudin-5 expression is decreased (A’ 
and B’: cross sectional). DAPI (blue) is shown in A-D and merged images in A’’’-D’’’. Bars: 20 μm. 
 
FIGURE 3. Confocal microscopy images of TJP ZO-1 (green) and CD31 (red) of CCMs (CCM#2, 
CCM#3) and in control specimens (c#1, c#4). Like As in control tissue section stainings for occludin 
and claudin-5, ZO-1 is distributed in a typical linear vessel pattern (C’: cross sectional; D’: 
longitudinal). In contrast, ZO-1 is significantly decreased (A’-B’: cross sectional) in CCM samples. 
DAPI (blue) is mapped in A-D and merged images in A’’’-D’’’. Bars: 20μm. 
 
Fig4: Confocal imaging of cryosections of CCM (CCM#1, CCM#6) and control tissues (c#1, c#5) 
immunostained for GLUT-1 (green) and CD31 (red). In control vessels, GLUT-1 is distributed 
uniformly (C’: cross/longitudinal; D’: longitudinal). However, the glucose transporter 1 is massively 
downregulated in CCM tissue samples (A’: cross sectional; B’: cross/longitudinal). DAPI (blue) is 
mapped in A-D and merged images in A’’’-D’’’. Bars: 20μm. 
 
FIGURE 4. Immunostaining for occludin (green) and collagen IV (red) on two CCM and NBT 
samples, respectively. Different phenotypes of occludin distribution are observed. Similar to control 
vessels, the linear pattern of occludin staining is preserved but thinned (A: longitudinal). To some 
extent, occludin is arranged in a punctate pattern along cell-cell contacts (B: longitudinal). At other 
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foci, vessels are completely unstained along the major length of their profile but show isolated, 
residual protein aggregates (C: cross sectional). Occludin is distributed in a linear pattern in 
microvessels of the adult human brain (cerebral cortex) (D and E). Basement membranes of capillaries 
are labeled by collagen IV-antibody (A-E). Nuclear staining with TO-PRO3 (blue) is shown in A-E. 
Bars: A, B and D, E 25 μm; C 10 μm. 
 
FIGURE 5. Immunostaining for claudin-5 (green) and collagen IV (red) on two CCM specimens and 
NBT. In most instances, vessels appear negative for claudin-5. At some foci, claudin-5 is diffusely 
distributed within the tissue and not localized to intercellular contact sites (A: cross sectional). Few 
vessels show a punctate staining pattern (B: cross sectional). Decreased claudin-5 staining is seen 
along the EC cell contacts (C: cross sectional). Linear claudin-5 staining in capillaries of control NBT 
(D: longitudinal). Basement membranes of microvessels are labeled by collagen IV-antibody (A-D). 
Nuclear staining with TO-PRO3 (blue) is shown in A-C. Bars: A/D 30 μm; B/C 10 μm.  
 
FIGURE 6. Confocal imaging of cryosections of CCM (CCM#1, CCM#6) and NBT (c#1, c#5) 
immunostained for GLUT-1 (green) and CD31 (red). In control vessels, GLUT-1 is distributed 
uniformly (C’: cross/longitudinal; D’: longitudinal). However, the glucose transporter 1 is massively 
downregulated in CCM tissue samples (A’: cross sectional; B’: cross/longitudinal). DAPI (blue) is 
mapped in A-D and merged images in A’’’-D’’’. Bars: 20μm. 
 
FIGURE 7. Localization of fibronectin (green) and collagen VI as EC-marker (red: A’’-B’’) in CCM 
specimens: CCM#5 (A) and control: c#1 (B) by confocal microscopy. In vessels of the control tissue,  
fibronectin is distributed regularly (B’: cross sectional). In CCM endothelial cells, fibronectin 
expression is impaired and irregular (A’: cross sectional). DAPI (blue) is shown in A+B and merged 
images in A’’’+B’’’. Bars: 20 μm. 
 
Fig7:FIGURE 8. Analysis of FI of occludin, claudin-5, ZO-1 and GLUT-1 stainings in cryosections 
of CCMs and control tissues. Experiments were done in triplicates. (A) MFI of each CCM and control 
specimen; (B) MFI (in %) of the seven normalized CCM specimens versus controls. Mean control 
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MFI was calculated as 100% (mean ± standard error of mean). Changes in MFI were calculated as 
highly significant for all proteins examined (students t-test, p < 0.0001, ****). 
 
Fig8:FIGURE 9. Relative mRNA expression (by microarray analysis) of occludin, claudin-5, ZO-1 
and GLUT-1 in CCM and NBT. Mean value of relative mRNA levels of four EC-markers were 
calculated. Values for expression levels of named genes were consequently divided by the value of 
EC-markers. Calculation was done for each CCM (n=6) and STA (n=3) specimen. Data is shown as 
mean values ± SEM of two individual experiments with eight samples in each group. Data were 
normalized against the EC-marker gene CD31. mRNA expression levels from NBT (n=8) are set to as 
100% (mean  standard error of the mean). Differences in mRNA concentrations were determined by 
the Mann-Whitney-Wilcoxon test with p < 0.05 being considered statistically significant.   
 
Legends to supplementary figures 
 
FIGURE S1. Confocal imaging of paraffin sections of CCM (CCM#1) and NBT (c#1) 
immunostained for occludin (green) and vWF (red). In control vessels, occludin is distributed in a 
linear pattern (C’: cross sectional; D’: longitudinal). However, occludin is massively downregulated in 
CCM tissue samples (A’ and B’: cross sectional). DAPI (blue) is mapped in A-D and merged images 
in A’’’-D’’’. Bars: 20μm. 
 
FIGURE S2. Immunostaining for GLUT-1 (green) and vWF (red) in paraffin embedded CCM and 
NBT specimens (CCM3; c1). Decreased or absent GLUT-1 staining is seen in vessels of CCM 
tissue (A’ and B’: cross sectional). In capillaries of control NBT, GLUT-1 is distributed uniformly 
(C’: cross sectional; D’: longitudinal). ECs are labelled against the marker protein vWF (A’’-D’’). 
Nuclear staining with DAPI (blue) is shown in A-D. Bars: 20 μm.  
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Table 1: Primer sequences for qRT-PCR 
occludin  forward CACACAGGACGTGCCTTCAC 
occludin reverse GAGTATGCCATGGGACTGTCAA 
claudin-5 forward CTGCTGGTTCGCCAACATT 
claudin-5 reverse TGCGACACGGGCACAG 
ZO-1 forward CAGCCGGTCACGATCTCCT 
ZO-1 reverse TCCGGAGACTGCCATTGC 
GLUT-1 forward TGCTCATGGGCTTCTCGAA 
GLUT-1 reverse AAGCGGCCCAGGATCAG 
CD31 forward TCTCCCAGCCCAGGATTTC 
CD31 reverse TTCGATGGTCTGTCCTTTTATGAC 
vWF forward  AGAAACGCTCCTTCTCGATTATTG 
vWF reverse TGTCAAAAAATTCCCCAAGATACA 
Table
Table 2: Clinical findings of enrolled patients in the study (40) 
                    
           
Patient baseline characteristics     Characteristics of CCM lesions   
                    
           
patient no. 
age/sex ethnicity clinical 
presentation 
radiological 
findings family history lesion location 
size (diameter in 
mm) 
multiple 
lesions DVA/associated 
                    
           
CCM#1 38M caucasian SH RH non Rt. parietal 29 N N 
CCM#2 23F caucasian SH RH non Rt. brachium pontis 10 Y N 
CCM#3 48F caucasian SH NRH yes Lt. brachium pontis 12 Y N 
CCM#4 34F caucasian NH-FND NRH non Lt. pedunculus cerebr 14 N Y/Y 
CCM#5 36F caucasian SH RH non Lt. insular  9 N Y/Y 
CCM#6 6M caucasian SH NRH non Rt. pons 23 N N 
CCM#7 14F caucasian SH NRH non Rt. pons 20 N N 
CCM#8 35F caucasian NH-FND NRH non Lt. pons 15 N Y/Y 
CCM#9 7 F caucasian NH-FND NRH non Rt. subinsular 20 N N 
CCM#10 27 F caucasian SH RH non Lt. pons 15 N Y/Y 
CCM#11 39M caucasian NH-FND RH non Rt. occipital 20 N N 
CCM#12 47 F caucasian SH NRH non Pons 17 N Y/Y 
 
M, male; F, female; SH, symptomatic hemorrhage; NH-FND, non-hemorrhagic focal neurological deficit; RH, recent hemorrhage; NRH, no recent hemorrhage; DVA, developmental venous anomaly; Y, yes; N, no. 
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